Aman's Global Market Intelligence

1 · Executive dashboard

Risk-on, fragile

Regime call: price action was decisively risk-on—record S&P close, broad positive breadth, falling VIX and technology leadership—but macro fundamentals are not unambiguously bullish. July payrolls fell 23,000, participation is only 61.4%, and Wednesday CPI can quickly reverse the duration rally. Treat the record tape as constructive evidence, not permission to chase.

S&P 5007,757.64+0.62% Fri · +3.58% wk

Nasdaq Composite26,690.62+1.30% Fri · +5.19% wk

Dow Jones54,036.93+0.28% Fri · +2.96% wk

Russell 20003,034.49+1.10% Fri · +3.52% wk

VIX14.90−1.65% Fri · −6.82% wk

U.S. 2Y · 17:05 ET4.199%−4.6 bp Fri

U.S. 10Y · 17:05 ET4.649%−2.1 bp Fri

DXY proxy close99.60−0.20% wk

WTI Sep proxy$78.18−7.67% wk

Gold Dec proxy$4,340.70+7.20% wk

Market	Aug. 7 close	Weekly move	Read-through
Nikkei 225	65,606.71	+1.93%	Positive, volatile week
Hang Seng	25,668.03	−0.84%	Lagged global risk rally
Shanghai Composite	3,940.04	+2.81%	Mainland outperformed Hong Kong
Kospi	6,258.77	−5.10%	Sharp regional laggard
STOXX Europe 600	660.25	+1.70%	Fourth straight record close Friday
Euro STOXX 50	6,523.86	+2.61%	Large-cap strength
DAX	26,319.45	+2.69%	Near record territory
FTSE 100	10,901.10	+0.30%	Underperformed Europe

1 · Labor shock, bullish rate reaction

BLS reported −23,000 payrolls versus +80,000 Reuters consensus, 4.1% unemployment, 3.2% y/y wages and −103,000 combined revisions to May/June. Yields fell and equities rose as September hike odds dropped to about 44%.

2 · Earnings breadth validated

Reuters/LSEG counted 85.1% of 436 reporting S&P companies above expectations. Advancers beat decliners 2.49:1 on NYSE and 2.07:1 on Nasdaq Friday—better evidence than index concentration alone.

3 · CPI is next gate

Wednesday July CPI and Thursday PPI test whether weaker labor can coexist with easing inflation. Reuters consensus: 3.4% headline and 2.5% core y/y CPI. Oil's weekly decline helps, but gold's surge flags residual hedging demand.

2 · Weekly performance audit

First mention: Aug. 7 report; one session only

Method: Friday's report was published before the jobs release and used Aug. 6 closes as baselines. Close-to-close return is measured from Aug. 6 to Aug. 7. MFE/MAE use Friday's intraday high/low versus that baseline and are aligned to the call direction. This tiny sample is not statistically meaningful.

Call / baseline	Aug. 7 close	Result	MFE / MAE	Status & calibration
NVDA conditional bullish $218.99 · C77	$223.96 +2.27%	Direction correct	+2.64% / 0.00% low stayed +0.76%	Active; $217 hold and $223.63 breakout conditions were met. Keep long-term thesis; avoid extrapolating one day.
LLY bullish long-term $1,191.94 · C82	$1,185.71 −0.52%	Short-term direction wrong	+0.41% / −2.58%	Long-horizon thesis intact; Friday low $1,161.20 briefly broke the stated $1,174 support, so swing confidence is cut.
RGTI avoid / bearish bias $16.53 · C74	$17.94 +8.53%	Direction wrong	+0.76% / −8.59%	Failed one-day bearish call. Price closed above $17.14 invalidation with volume; remove bearish timing, retain valuation warning only.
IONQ avoid $39.72 · C72	$44.43 +11.86%	Direction wrong	0.00% / −12.32% low was still +0.70%	Avoid stance was costly for opportunity. No short thesis was issued. Downgrade confidence; require business conversion evidence, not price fighting.
VKTX speculative watch $33.30 reference	$34.26 +2.88%	Not scored	N/A	No directional call and no full-data catalyst occurred; watch remains active.

Scorecard: 1 correct, 2 wrong among three directional calls; LLY was explicitly long-term but is shown as wrong for Friday transparency. One non-directional watch is unscored. The lesson is clear: valuation shorts/avoids can underperform badly in a broad speculative rally; wait for price confirmation rather than assuming mean reversion.

3 · Market-moving analysis

Confirmed facts vs inference

Confirmed

Payrolls declined 23,000; unemployment was 4.1%; participation 61.4%; wages +3.2% y/y. Prior two months were revised down 103,000.
Fed hike pricing for September fell to about 44% from 55% Thursday, according to Reuters citing CME.
WTI ended below $80 and the 10Y near 4.65%; U.S.-Iran diplomacy helped ease the oil inflation channel.
S&P, Nasdaq and Dow posted their biggest weekly percentage gains since April; S&P and Nasdaq closed at records.
STOXX 600 hit a fourth consecutive record close; LSEG expects Q2 European corporate profit growth above 22%.

Inference / portfolio use

Goldilocks or slowdown? The market chose lower-rate optimism, but falling participation and negative payrolls can become an earnings problem if persistent.
Inflation asymmetry: a benign CPI can extend tech leadership; a hot print would challenge both the Fed-relief narrative and elevated multiples.
Oil remains geopolitical convexity: durable de-escalation is positive for duration; renewed Hormuz restrictions would lift inflation risk quickly.
Breadth supports—but does not immunize—the rally: Friday breadth was strong, yet VIX 14.90 suggests little near-term protection is priced.
Do not confuse earnings beats with easy upside: AMD fell despite objectively good results because expectations were higher.

4 · Thematic dashboards

AI infrastructure Leadership

Performance: SMH +7.80% and IGV +8.57% for the week; NVDA +11.56%.
Verified demand: Kingspan surged 17.8% Friday after raising profit guidance on booming data-center demand; AI demand supported Cloudflare and Airbnb reactions.
Next tests: CRWV Aug. 11, CSCO Aug. 12, AMAT Aug. 13; NVDA Aug. 26.
Laggard lesson: AMD data-center revenue more than doubled to $6.72B, yet shares fell as expectations and supply constraints dominated.
Risk: SOX is +70% in 2026 but still over 15% below its late-June high; power, packaging, export policy and capex returns remain key.

Quantum computing Momentum > economics

Performance: IONQ +21.93% and RGTI +20.00% for the week; both jumped again Friday.
RGTI facts: Q2 revenue $5.1M, operating loss $28.1M, liquidity $541.3M, no debt; potential Commerce funding remains an LOI and contemplates government equity.
IONQ facts from prior primary-source review: Q2 revenue $80.1M; 2026 guide $280–290M; adjusted EBITDA loss $120.3M.
Risk: cash gives runway, not valuation support. Government awards, roadmaps and acquisition synergies must convert to durable revenue/margins.

Peptide / metabolic biotech Demand strong

Performance: XBI +7.05%, XLV +1.93%, LLY +3.21%, VKTX +7.94% weekly.
Leader: Lilly's previously verified Q2 revenue rose 48%; Mounjaro +91%, Zepbound +46%.
Competition: Novo raised its outlook, but pipeline setbacks and weaker-than-expected pill sales drove concern; management promised faster R&D and bolt-on deals.
VKTX: Phase 3 trials are registered; Q3 maintenance data timing remains unspecified. Cash and tolerability details must be checked in the eventual full release.
Risk: binary efficacy/safety, reimbursement, manufacturing, dilution and litigation—not just total-addressable-market narratives.

5 · Ranked ideas for next week

Conditional research setups

#1 NVDA · NVIDIA Bullish / confirmation

Nasdaq · approx. $5.4T mega-cap · AI compute/networking · high event/valuation risk

Day: only after CPI reactionSwing 1–4 weeks: applicableInvestment 3–12+ months: applicable

Thesis / direction: may continue to outperform if inflation is benign and infrastructure earnings validate demand.

Catalyst / evidence: CRWV/CSCO/AMAT read-through; company-confirmed Aug. 26 earnings; +11.56% week and Friday breakout above prior $223.63 trigger.

Counterargument: record tape and mega-cap valuation demand near-perfect execution; export, customer concentration and capex-return risks persist.

Context: $223.96 close, $224.76 Friday high, near $236.54 52-week high; strong momentum is also chase risk.

Entry / confirmation: require post-CPI hold above $220.66 Friday low or high-volume close above $224.76.

Invalidation / downside: close below $217 or sharply higher 10Y; guidance deceleration invalidates investment thesis. Gap risk toward prior consolidation.

Principal risks: CPI/yields, earnings gap, regulation, supply/power constraints.

Confidence

Risk

Opportunity

Confidence: demand/primary catalyst strong, macro-dependent. Opportunity: leadership + catalyst. Risk: valuation/event concentration.

#2 LLY · Eli Lilly Bullish long-term / patience

NYSE · approx. $1.1T mega-cap · peptide/metabolic drugs · policy, competition and valuation risk

Day: no edgeSwing: confirmation neededInvestment 3–12+ months: applicable

Thesis / direction: verified incretin growth may support long-run compounding, but Friday's failed support reduces near-term edge.

Catalyst / evidence: Q2 revenue +48%, Mounjaro +91%, Zepbound +46%; competitor pipeline and prescription updates.

Counterargument: premium multiple, Novo/oral competition, pricing, manufacturing and safety can outweigh growth.

Context: $1,185.71 close; Friday range $1,161.20–$1,196.80; +3.21% week after earnings volatility.

Entry / confirmation: require close above $1,196.80, or base above $1,161.20; do not average blindly into a breakdown.

Invalidation / downside: sustained close below $1,161 plus estimate cuts; demand, safety or reimbursement deterioration invalidates. Premium reset can be material.

Principal risks: pricing/policy, competition, manufacturing, safety, litigation.

Confidence

Risk

Opportunity

Confidence cut 3 points after support failure; fundamentals remain the strongest component.

#3 RGTI · Rigetti Avoid chasing; no short trigger

Nasdaq · approx. $6B speculative small/mid-cap · quantum · very high volatility/dilution/squeeze risk

Day: avoidSwing: no actionable shortInvestment: milestones only

Thesis / direction: operating economics do not support chasing +20% weekly momentum; direction is uncertain and the prior bearish timing failed.

Catalyst / evidence: $5.1M revenue versus $28.1M operating loss; $541.3M liquidity; up-to-$100M Commerce LOI not final and may involve equity.

Counterargument: cash, no debt, HPE/PSC deployment, government support and technical milestones can sustain strategic premium.

Context: $17.94 close at Friday high $17.95 on ~29.9M shares; prior bearish invalidation was decisively breached.

Confirmation: avoid chasing. Reconsider only after funded awards and commercial conversion; bearish setup requires failed breakout and close below $16.40.

Invalidation / downside: valuation warning weakens on large recurring commercial wins and verified fidelity at scale. Long downside includes dilution/multiple collapse.

Principal risks: squeeze/borrow uncertainty, technical claims, dilution, government conditions. No borrow fee/availability asserted.

Confidence

Risk

Opportunity

#4 IONQ · IonQ Avoid at this price / not short

NYSE · approx. $16B speculative mid-cap · quantum · high execution/M&A/dilution risk

Day: avoid volatilitySwing: no edgeInvestment: watch conversion

Thesis / direction: +21.93% week magnifies valuation risk; revenue growth is real, but losses and integration require proof.

Catalyst / evidence: prior verified Q2 $80.1M revenue and $280–290M guide versus $120.3M adjusted EBITDA loss; Aug. 19 conference.

Counterargument: roughly $2B pro-forma liquidity and strong RPO can justify strategic premium if converted efficiently.

Context: $44.43 close; Friday range $40.00–$44.62 and +11.86%; momentum invalidated prior avoid timing.

Confirmation: require narrowing cash burn and durable gross-margin mix, or valuation reset; no short without a failed breakout.

Invalidation / downside: avoid view changes on verified margin inflection. Downside includes M&A complexity, dilution and multiple compression.

Principal risks: squeeze/borrow uncertainty, technology roadmap, procurement timing. No borrow terms asserted.

Confidence

Risk

Opportunity

Watchlist — confirmation needed

AMAT · Applied Materials Watch

Nasdaq · mega-cap equipment · AI enabler · moderate-high cycle/export risk

Horizons: day/swing after Aug. 13 only. Thesis: may benefit from advanced-node, memory and packaging spend. Catalyst: company-confirmed Aug. 13 results. Evidence: Q2 diluted EPS $3.51 vs $2.63 prior-year in its filing snapshot. Counter: China/export and capex-cycle risk.

Confirm: guidance plus high-volume price hold; no pre-earnings chase. Invalidation/downside: order/guidance contraction; earnings gap. Risks: export rules, concentration, cyclicality.

CSCO · Cisco Watch

Nasdaq · mega-cap networking · AI/data-center · moderate risk

Horizons: swing/investment after results. Thesis: AI networking/orders may improve mix. Catalyst: company-confirmed Aug. 12, 16:30 ET. Evidence: primary IR calendar; sector networking demand is supportive. Counter: enterprise cyclicality and AI competition.

Confirm: orders, guidance and margins—not headline AI mentions. Invalidation/downside: weak orders or guide; earnings gap. Risks: competition, integration, macro.

VKTX · Viking High-risk speculative

Nasdaq · approx. $4B clinical-stage biotech · peptide obesity · binary/dilution risk

Horizons: swing catalyst watch; investment only risk-sized. Thesis: maintenance data could differentiate VK2735. Catalyst: Q3 timing unspecified; Phase 3 trials registered. Counter: pre-revenue versus scaled incumbents.

Confirm: full randomized durability, safety, discontinuation and dose-response data. Invalidation/downside: weak durability/safety, delay or financing; large gap possible. Biotech risks: Phase 3 execution, endpoints, competition, manufacturing, runway/dilution.

6 · Changes since Friday

Regime upgraded from neutral/event-risk to risk-on/event-sensitive after record closes, strong breadth and lower yields—but CPI is an immediate invalidation checkpoint.
NVDA: bullish conditions met; confidence 77→78, with entry discipline tightened after an 11.56% weekly run.
LLY: investment thesis retained; confidence 82→79 because Friday broke stated swing support intraday.
RGTI: bearish timing invalidated above $17.14; confidence 74→57 and classification changed to “avoid chasing / no short trigger.”
IONQ: avoid timing failed; confidence 72→56. Do not fight momentum without a technical failure and business evidence.
AMAT and CSCO added as earnings watches; no pre-event trade is forced. VKTX remains a speculative watch.

7 · 7–30 day catalyst calendar

Times ET unless noted

Aug. 11 · 17:00 — CoreWeave Q2 results

Company-confirmed. AI-cloud demand, backlog quality, capex financing, utilization and customer concentration.

Aug. 12 · 08:30 — July CPI / real earnings

BLS-confirmed. Reuters consensus: 3.4% headline, 2.5% core y/y. Primary cross-asset gate.

Aug. 12 · 16:30 — Cisco Q4 FY26 results

Company IR-confirmed. AI networking orders, enterprise demand and guidance.

Aug. 13 · 08:30 — July PPI

BLS-confirmed. Tests pipeline inflation one day after CPI.

Aug. 13 · 16:30 — Applied Materials Q3 call

Company-confirmed. Foundry/logic, memory, advanced packaging, China/export commentary.

Aug. 14 · 08:30 — July retail sales

Census-confirmed. Determines whether labor weakness is reaching consumption.

Aug. 19 · 14:00 — FOMC minutes

Fed-confirmed. Watch the division after three policymakers favored a hike in July.

Aug. 19 — IonQ at Needham semiconductor conference

Company-listed in prior report; verify same-day details. Focus on conversion and integration, not promotional roadmap claims.

Aug. 26 · 14:00 PT — NVIDIA Q2 FY27 results

Company-confirmed. Data-center growth, supply, networking, margins and forward guidance.

Aug. 26 · 08:30 — GDP second estimate + July income/PCE

BEA-confirmed. Inflation and real-demand update.

Q3 · exact date unavailable — Viking VK2735 maintenance data

Company guidance from prior report; no exact release date found. Do not position as if timing were confirmed.

FDA/clinical note: third-party FDA calendars list multiple August decisions, but no peptide-theme PDUFA was verified from an FDA or company primary source during this run. They are therefore excluded from actionable ideas. ClinicalTrials.gov confirms VK2735 Phase 3 registrations, not a maintenance-data release date.

8 · Bottom line

Current-session/day trade

No weekend trade. For Monday, do not infer direction from thin indications. The cleaner setup is post-CPI Wednesday: NVDA only if $220.66 holds and yields do not surge; otherwise cash is valid.

1–4 week swing

NVDA on confirmation remains the best evidenced setup, with CSCO/AMAT as event watches rather than anticipatory bets. Biggest risk is a hot CPI/PPI plus renewed oil pressure.

3–12+ month investment

LLY on disciplined pullbacks has the strongest verified operating momentum. View changes with demand/estimate deterioration, safety, reimbursement or manufacturing problems.

What changes the regime: benign inflation, stable/falling 10Y and persistent breadth would sustain risk-on. CPI above expectations, 10Y moving decisively back above 4.70%, oil shock, or shrinking breadth at new index highs would downgrade to neutral/risk-off. Biggest risk: markets are pricing rate relief from weak jobs while VIX is low; a stagflationary inflation surprise attacks both the growth and valuation pillars.

Sources & data quality

Data-quality panel

U.S. index closes, breadth, volume and weekly gains were cross-checked between Reuters and Yahoo chart data. Individual audit closes were cross-checked with CNBC for NVDA, LLY, IONQ and VKTX; Yahoo supplied complete OHLC data. Nasdaq historical endpoint rejected future-dated query parameters; Stooq presented a JavaScript proof-of-work gate.
CNBC/Tradeweb provided Aug. 7 17:05 ET Treasury yields. The official Fed H.15 release dated Aug. 7 only contained observations through Aug. 6, so it is used for historical validation, not Friday's close.
Oil, gold and DXY are Yahoo chart proxies and may reflect futures/index settlement conventions different from a spot quote. They are decision context, not executable prices.
Market-cap figures are approximate. RGTI/IONQ market values are especially unstable because prices and diluted share counts move materially.
One prior report is available, so the audit starts Aug. 7. This remains the initial two-week paper-tracking phase.